News
Conclusion of the decentralised marketing authorisation procedure for Salmex in Scandinavian countries
The procedure included: Sweden, Finland, Norway, Denmark and Iceland. The Company’s business partner in the scope of obtaining marketing authorisation and product distribution in the markets covered by the DCP is Glenmark. The countries covered by the Scandinavian procedure have issued positive decisions on acceptance of the submitted marketing authorisation dossier. Bogdan Manowski, Director forRead more »
Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression
20171128_Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression
Maciej Wieczorek receives the Economic Award granted by the President of the Republic of Poland
Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A. received an individual Economic Award granted by the President of the Republic of Poland. The Award was handed in during the “Congress 590” in Rzeszów. It is a distinction in the area of economy which has been awarded by the President of the RepublicRead more »
Stable business foundation with a good prospect for presence in new European markets.
20171115_ Stable business foundation with a good prospect for presence in new European markets.
Jerzy Peczykolan at the Congress of the “World of the Pharmaceutical Industry”
The Head of the Department of Preclinical Trials at Celon Pharma was a speaker at the 9th Congress of the “World of the Pharmaceutical Industry”. The subject of his presentation was: Opportunities for the development of innovative therapies in Poland in the light of global R&D trends The Congress of the “World of the PharmaceuticalRead more »
Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes
Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking. This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests,Read more »
Maciej Wieczorek at the “Technologies of the Future – Biotechnology” conference
The CEO of Celon Pharma S.A. was a guest of the expert debate held during the Conference: Techonologies of the Future – Biotechnology, which was held on 19 October at the Presidential Palace devoted to the role of biotechnology and perspectives of its development in Poland. We are here today because we believe in biotechnology,Read more »
Announcement of the Management Board of Celon Pharma S.A.
Ladies and Gentlemen, In connection with the information provided yesterday by Selvita S.A. on withholding the clinical programme for SEL24, the Management Board of Celon Pharma S.A. informs that such situations occur naturally in the process of creating innovative medicinal products, as demonstrated by numerous examples of clinical projects carried out in American or EuropeanRead more »
Celon Pharma S.A. at the 23rd Scientific Congress of the Polish Pharmaceutical Society
The event covered a broad scope of issues which are the subject of scientific research in response to challenges faced by the modern pharmaceutical sector. At the congress, Mikołaj Matłoka – Leader of the Neuropsychiatry Research Group at Celon Pharma S.A. – presented issues related to the development of innovative drugs in neuropsychiatric indications.Read more »
An interview with Maciej Wieczorek in inwestorzy.tv
President of the Board of Celon Pharma S.A. was a guest of the programme Profit. He answered Agniszka Zaręba’s questions on the company’s results for the first half of 2017, on its presence in international markets and the strategy of global commercialisation of the company’s innovative portfolio. We invite you to view the video.